Joint Statement of the German Radiological Society and the German Respiratory Society on a Quality-Assured Early Detection Program for Lung Cancer with Low-dose CT.
[Joint Statement of the German Radiological Society and the German Respiratory Society on a Quality-Assured Early Detection Program for Lung Cancer with Low-dose CT]. Pneumologie. 2019 Sep 19;: Authors: Herth FJF, Reinmuth N, Wormanns D, Antoch G, Biederer J, Vogel-Claussen J, Kauczor HU, Pfeifer M, Vorstand der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin, Vorstand der Deutschen Röntgengesellschaft Abstract Substantial new data on early detection of lung cancer with low-dose CT has become available since the last joint statement of the German Roentgenological Society and the German Respiratory Society was published in 2011. The German S3 guideline on lung cancer was revised in 2018 and now contains a weak recommendation towards early detection of lung cancer with low-dose CT in a quality-assured early detection program. These new developments required a repositioning of the involved professional societies. This present joint statement describes main features of a quality-assured program for early detection of lung cancer with low-dose CT in Germany. PMID: 31537020 [PubMed - as supplied by publisher]
Conclusions: SIF + XRT caused changes in patterns of endothelial cell death and survival, proinflammatory molecule release, and adhesion molecule expression at early time points post-XRT associated with early reduction of immune cell recruitment. These findings suggest that SIF could mediate its radioprotective effects in irradiated lungs by limiting excessive immune cell homing via vascular endothelium into damaged lung tissue and curtailing the overall inflammatory response to radiation. PMID: 31633433 [PubMed - as supplied by publisher]
This study aimed to investigate how bevacizumab, a vascular endothelial growth factor A (VEGFA) neutralizing antibody applied in clinic, affects the tight junction protein CLDN5 and subsequently influences tumor cell invasion and potential metastasis. Western-blot, quantitative real-time polymerase chain reaction (q-PCR), immunofluorescence and immunohistochemistry revealed that low-dose bevacizumab up-regulated CLDN5, whereas high-dose bevacizumab down-regulated CLDN5. Cell migration, invasion and permeation assay demonstrated that high-dose bevacizumab enhanced the migration, invasion and permeation abilities of human um...
Authors: Yang Y, Zheng H, Zhan Y, Fan S Abstract Traditionally, the metastasis has been detected in the late stage of the cancer, which mostly leads to death. The classical opinion about tumor metastasis is that tumor cell migration begins with the single tumor cell and goes through a series of complicated procedures, and lastly arrives and survives at distant tissues and organs. However, emerging studies have found a new migration mechanism called collective cell migration in many cancers. The collective cell migration could move as clusters with the tight cell-cell junction in the tumor microenvironments, toward ...
In conclusion, our findings proved that XIST can serve as a tumor promoter in the pathogenesis of NSCLC, suggesting that XIST has the potential to become a novel therapeutic target for the treatment of NSCLC. PMID: 31632587 [PubMed]
In conclusion, our study found the critical regulation of lncRNA LINC00337 for the NSCLC through epigenetic regulation, which may serve as a predictive biomarker and potential therapeutic target. PMID: 31632575 [PubMed]
Authors: Kozuma Y, Toyokawa G, Yamada Y, Shoji F, Yamazaki K, Oda Y, Takeo S PMID: 31632774 [PubMed]
Authors: Windisch P, Guckenberger M PMID: 31632771 [PubMed]
Authors: Liam CK, Poh ME, Liam YS PMID: 31632766 [PubMed]
Authors: Lamberti G, Andrini E, Ricciuti B PMID: 31632761 [PubMed]
Authors: Kerdidani D, Magkouta S, Tsoumakidou M PMID: 31632820 [PubMed]